Stemline Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and Europe. The company offers ELZONRIS, a targeted therapy directed at the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults and in pediatric patients two years of age and older. The company provides ORSERDU for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, HER2-negative, and ESR-1-mutated advanced or metastatic breast cancer. It also develops CD123, which is in Phase I/II clinical trials for the treatment of chronic myelomonocytic leukemia and myelofibrosis, as well as acute myeloid leukemia and multiple myeloma, in combination with other therapies. In addition, the company is developing SL-801, a novel oral small-molecule reversible inhibitor of nuclear transport protein, which is in Phase I clinical trials for the treatment of solid and hematologic cancers, and SL-701, an immunotherapy that has completed Phase II clinical trials to treat brain cancer. Its preclinical pipeline products include SL-501, a CD123-targeted therapy; SL-1001, an oral, selective small-molecule RET kinase inhibitor targeting multiple oncology indications; and SL-901, a small molecule kinase inhibitor. The company was incorporated in 2003 and is based in New York, New York. Stemline Therapeutics, Inc. operates as a subsidiary of Berlin-Chemie AG.